Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2023 Earnings Call Transcript

Scott Wolchko: Yes. We are working through that. I can think one of the strategies, quite honestly, with respect that we have heard, in speaking with folks in the field is that, in these early days, they really do like to partner as much as they can with an oncologist that has significant experience in CAR T-cell therapy. And so for us, as you know, we are running the 819 study in oncology and I think, somewhere between 12 to 15 sites are open. And so as we think about, how to most effectively get 819 off the ground in autoimmunity, we are excited to partner with some of those sites as an example, who are very familiar with 819 are currently enrolling patients, and provide that sort of partnering opportunity with the oncologist and the rheumatologist to treat patients.

Operator: That concludes the question and answer session. I’d like to turn the call back over to Scott Wolchko for closing remarks.

Scott Wolchko: Thank you. And thank you all for participation in today’s call. Hope all of you make it out here for ASH in San Diego and happy to sit down and spend some time with you. Thank you very much.

Operator: Thank you. This concludes the program. Thank you for your participation. You may now disconnect. Everyone, have a great day.